Hormone refractory prostate cancer (report of 39 cases)

Zhongquan Sun,Weiqing Qian,Jianda Song,Jun Xu,Huixing Wu,Dansheng Xie,Lu Sheng,Haiyong Ding
DOI: https://doi.org/10.3969/j.issn.1008-0848.2006.06.012
2006-01-01
Abstract:Objective: To study diagnosis and treatment of hormone refractory prostate cancer and to improve the recognization of the disease. To find survival difference between patients from China and west countries. Methods: The clinical data of 39 cases from Jane 1995 to October 2004 were retrospectively analysed. Results: Serum PSA level of 38 patients were stepped-up from lowest when hormone refractory prostate cancer was diagnosed. But in four patients PSA level were always under 4ng/ml, diagnosis of HRPC of these patients relied on the appearance or enlargement of metastatic focus. Oral chemotherapy regimen using estramustine phosphate, etopside and cyclophosphamide were mainly treatment of hormone refractory prostate cancer patients in our group. PSA efficiency rate was range from 44.4% to 57.8%, and average effective time was range from 3.8 months to 7.5 months. Objective response rate was ranged from 28.6% to 50%. 21 cases were died, and medial duration of life was 16 months. Conclusion: Almost all HRPC patients can be diagnosis and follow up by serum PSA. Chemotherapy was the major therapy for treating HRPC. Oral combination regimen with two drugs have nice effect. Medial survival time of HRPC patients from China maybe longer than those from west world.
What problem does this paper attempt to address?